目前和未来的初级胆道胆道炎的管理机会
Sandra Naffouj1, Jennifer Wang1
1Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois, Chicago, IL, United States.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
原发性胆道胆炎 (PBC) 是一种慢性肝病. 虽然ursodeoxycholic acid (UDCA) 是标准的,但有些患者需要额外的疗法,如obeticholic acid (OCA) 或PPAR激动剂,以获得更好的结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 初级胆道胆炎 (PBC) 是一种罕见的,免疫媒介的慢性胆固醇性肝病.
- 如果不治疗,可能导致肝纤维化和肝硬化.
- 对于PBC的确切发病因仍然不完全理解,限制了治愈治疗的选择.
研究的目的:
- 审查最近关于在 UDCA 反应不足的患者治疗 PBC 的数据.
- 讨论目前正在PBC早期开发的新疗法.
主要方法:
- 对最近的临床数据和正在进行的研究进行文献综述.
- 对没有响应标准护理的PBC患者的治疗策略的分析.
主要成果:
- 乌尔索多西胆酸 (UDCA) 改善了结果,但在三分之一的PBC患者中无效.
- 二线疗法,包括obeticholic acid (OCA) 和过氧体增殖器激活受体 (PPARs),在添加到UDCA时显示出希望.
- 新兴疗法正在研究,适用于反应不充分的患者.
结论:
- 很大一部分PBC患者对UDCA没有充分的反应.
- 用UDCA和OCA或PPAR等药物的组合疗法是不响应患者的可行策略.
- 对新型治疗剂的进一步研究对于改善PBC管理至关重要.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
456
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
456
Acute Pancreatitis II: Clinical Manifestations and Management
1.0K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.0K
Chronic Bowel Disorders: Introduction
871
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
871
Peptic Ulcer Disease IV: Management
604
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
604
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
